VF
NEUP

Virtu Financial’s Neuphoria Therapeutics NEUP Stock Holding History

Virtu Financial’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49K Buy
+12,033
New +$50.9K ﹤0.01% 1292
2023
Q4 		– Sell
-1,380
Closed -$45K – 2101
2023
Q3 		$45K Buy
+1,380
New +$29.7K ﹤0.01% 921

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Virtu Financial's NEUP Position: Q1 2026 in Review

Virtu Financial opened a new position in Neuphoria Therapeutics (NEUP) in Q1 2026: 12,033 shares worth $49K. The stake represents ﹤0.01% of the portfolio and ranks #1292 among its holdings. This is a return to the name: Virtu Financial previously reported a position in NEUP as recently as Q3 2023.

Virtu Financial first reported a position in NEUP in Q3 2023 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Virtu Financial held 12,033 shares of Neuphoria Therapeutics worth $49K as of Q1 2026.
  • Neuphoria Therapeutics was a new Virtu Financial position in Q1 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1292 holding.
  • Virtu Financial first reported a position in Neuphoria Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.